#1CANSORTIUM 4 FLUENT CANNABIS CARE April 2024 Investor Presentation#2disclaimer GENERAL • The information contained in this presentation has been prepared by Cansortium Inc. ("Cansortium" or the "Company") and contains information pertaining to the business, operations, assets and prospects of the Company. The information contained in this presentation (a) is provided as at the date hereof and is subject to change without notice, (b) does not purport to contain all the information that may be necessary or desirable to fully and accurately evaluate an investment in the Company, and (c) is not to be considered as a recommendation by the Company that any person make an investment in Cansortium. Other than as may be required by applicable laws, the Company is under no obligation to update any information included in this presentation. An investment in the securities of the Company is speculative and involves a number of risks. • Other than as may be authorized by the Company upon request, this presentation may not be reproduced, in whole or in part, in any form or forwarded or further distributed to any other person. Any forwarding, distribution, or reproduction of this presentation in whole or in part is unauthorized. The Company takes no responsibility for and provides no assurance as to the reliability of, any information that others may give readers of this presentation. • This presentation does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. The securities described in this document have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons (as such term is defined in Regulation S under the U.S. Securities Act "U.S. Persons"), unless an exemption from such registration is available. • The securities described in this document have not been approved or disapproved by the U.S. Securities and Exchange Commission, or any other securities commission or regulatory authority in the United States, nor have any of the foregoing authorities or any Canadian provincial or territorial securities regulator passed upon or endorsed the merits of the securities nor have they approved this presentation or confirmed the accuracy or adequacy of the information contained in this presentation. Any representation to the contrary is a criminal offense. • Cannabis is a Schedule I controlled substance under the U.S. Controlled Substances Act and is illegal under U.S. federal law, the laws of certain U.S. states, and many foreign jurisdictions. Even in those U.S. states where cannabis has been legalized or decriminalized, it remains criminal under U.S. federal law. Companies participating in the regulated cannabis industry are subject to a myriad of risks as a result of applicable laws and regulations, including, without limitation, the risk of criminal prosecution and asset seizure, burdensome tax liabilities, lack of access to banking services, and an inability to enforce certain creditor and intellectual property rights, any of which may adversely affect the Company's operations and financial performance. FORWARD LOOKING INFORMATION • Certain statements in this presentation constitute forward-looking statements and forward-looking information within the meaning of applicable Canadian and United States securities legislation (collectively herein referred to as "forward-looking statements"), which can often be identified. by words such as "will", "may", "estimate", "expect", "plan", "project", "intend", "anticipate", "target", "believe", "continue", "outlook", "forecast" and other words indicating that the statements are forward-looking. Such forward-looking statements are expectations only and are subject to known and unknown risks, uncertainties, and other important factors that could cause the actual results, performance, or achievements of the Company or industry results to differ materially from any future results, performance or achievements implied by such forward-looking statements. Such risks and uncertainties include, among others, dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing state, local or other licenses; engaging in activities which currently are illegal under United States federal law and the uncertainty of existing protection from United States federal or further prosecution; regulatory or political change such as changes in applicable laws and regulations, including United States state-law legalization, particularly in Florida, due to inconsistent public opinion, perception of the medical-use and adult-use cannabis industries, bureaucratic delays or inefficiencies or any other reasons; any other factors or developments which may hinder market growth; the ability to complete proposed transactions and business plans as described, whether within proposed timeframes or at all; reliance on management; and the effect of capital market conditions and other factors on capital availability; competition, including from more established or better-financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with customers and suppliers. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although the Company has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events, or results to differ than those anticipated, estimated, or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company assumes no obligation to update any forward-looking statement, even if new information becomes available as a result of future events, new information or for any other reason except as required by law. • Historical statements contained in this document regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. In this regard, certain financial information contained herein has been extracted from, or based upon, information available in the public domain and/or provided by the Company. In particular historical results of the Company should not be taken as a representation that such trends will be replicated in the future. No statement in this document is intended to be nor may be construed as a profit forecast. USE OF NON-IFRS MEASURES • This presentation refers to non-IFRS financial measures, such as "EBITDA" and "Adjusted EBITDA", as defined below. The management of the Company believes that these non-IFRS financial measures in addition to conventional measures prepared in accordance with IFRS provides information that is helpful to understand the results of operations and financial condition of the Company. The objective is to present readers with a view of the Company from management's perspective by interpreting the material trends and activities that affect the operating results, liquidity, and financial position of the Company. These measures are not necessarily comparable to similarly titled measures used by other companies. "EBITDA" is earnings before interest, taxes, depreciation and amortization. "Adjusted EBITDA is equal to net income (loss), plus (minus) interest expense (income) and finance transactions costs, plus depreciation, and amortization, plus (minus) loss (gain) on disposal of capital assets, plus (minus) loss (gain) on foreign exchange, plus (minus) unrealized loss (gain) on embedded derivatives, plus (minus) certain one-time non- operating expenses, as determined by management. CANSORTIUM 2#3cansortium inc is a vertically-integrated cultivator, processor, formulator, and retailer of premium cannabis products. currently operating in florida, pennsylvania and texas under the FLUENT brand#4Operational Footprint Valuable Assets in Attractive U.S. Markets FLUENT TEXAS CULTIVATION LAB DELIVERY PENNSYLVANIA 3 DISPENSARIES FLORIDA CULTIVATION LAB 35 DISPENSARIES Investor Presentation 4#5Financial Highlights FY 2023 $97.3M FY2023 Revenue Up 11% vs. FY 2022 $27.2M FY 2023 Adj. EBITDA Up 8.5% vs. FY 2022 $18.5M FY 2023 Cash from Operations vs. $19.1M in 2022 FLUENT ($ in millions) Total Revenue FY FY YOY% 2022 2023 $ 87.7 $ 97.3 11% Adjusted EBITDA (1) $ 25.1 $ 27.2 8% (1) Adjusted EBITDA is a non-IFRS financial measure that does not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies. Investor Presentation 5#6Florida#7Deep Vertical Footprint FL FL FL FL SERVING PATIENTS IN CAPE CORAL CASSELBERRY CLEARWATER COCOA CORAL GABLES CORAL SPRINGS CRESTVIEW CUTLER BAY DAYTONA BEACH DEERFIELD BEACH EAST ORLANDO FORT MYERS FORT PIERCE FORT WALTON BEACH FRUITLAND PARK GAINESVILLE JACKSONVILLE (ATL BEACH) JACKSONVILLE (ATL BLVD) JACKSONVILLE (CASSAT) JACKSONVILLE (SAN JOSE) KENDALL LAKE WORTH LAKELAND MARY ESTHER MELBOURNE MIRAMAR BEACH NEW PORT RICHEY FLUENT FL FL FL FL FL FL FL FL OPERATIONS TAMPA HEADQUARTERS FL FL FL FL FL FL TAMPA FACILITY (GROW + LAB + DIST) SWEETWATER FACILITY (GROW PACKAGING) POLK CITY FACILITY (GROW) FL FL F RUSKIN FACILITY (GROW) NORTH MIAMI BEACH FL FL FL PANAMA CITY FL PENSACOLA 9 MILE ROSA FACILITY (GROW) F FL FL PENSACOLA DOWNTOWN <500k 500k. 1.5m 2.5m >2.5m ST PETERSBURG FL CURRENT DISPENSARIES TALLAHASSEE POPULATION BY COUNTY TAMPA CULTIVATION / OPERATIONS FL FUTURE DISPENSARY LOCATION Investor Presentation 7#8Cultivation and Processing Tampa Cultivation and Processing Facility Original facility 22,000 sq. ft. of indoor cultivation and 7,000 sq. ft. of production and administrative space Includes 20,160 sq. ft. of flowering canopy over six levels Additional ~22,500 sq. ft. facility brought online in 2022 including ~9,000 sq. ft. of new cultivation area Yield per harvest in Tampa has more than doubled since the start of 2022 Polk City Greenhouse Facility Existing ~25,000 sq. ft. greenhouse space with opportunity for additional expansion Produces high-quality CBD and THC oil Rosa and Ruskin Facilities Rosa: ~16,000 sq. ft. facility with ~7,000 of canopy upon completion of construction Ruskin: ~25,000 sq. ft. facility with ~3,400 of indoor cultivation and ~21,000 of greenhouse; operations began February 2024 ☐ ☐ Sweetwater Cultivation & Greenhouse Facility 26,000 sq. ft. indoor cultivation, production and administrative space with ~15,400 sq. ft. of indoor flowering canopy across 11 grow rooms Additional ~40,000 sq. ft. greenhouse Following the impact of Hurricane lan, Sweetwater is back to full functionality, operating ahead of pre-hurricane levels with latest harvests producing 30%+ THC flower potencies FLUENT Investor Presentation 8#9Pennsylvania#10Pennsylvania Summary ~12.8M Population ~$1.2B 2022 Sales Key Market Figures Pennsylvania is the 5th most populous state with 12.8mm people and is one of the largest and fastest growing medical markets in the country 2022 program sales were $1.2B compared to ~$1.3B for 2021 (1) " Regulatory Overview 50 dispensary permits exist and each permit allows up to 3 locations per region (150 total) with a maximum of 5 permits per single owner (15 total) In May 2020, Harper Polling found that 62% of Pennsylvanian likely voters favor legalizing marijuana Pennsylvania Governor Tom Wolf and U.S. Senator John Fetterman have been outspoken in their support for legalizing marijuana to reduce the budget deficit resulting from the Covid-19 pandemic >4x Increase In Patient Count(1) ~120% Increase In Open Dispensaries (1) (1) Source: BDSA, Canaccord Genuity, www.mpp.org FLUENT 169,000 712,000 Feb 2020 May 2022 77 171 Feb 2020 Jan 2023 Cansortium in Pennsylvania Cansortium holds one dispensary permit to operate in the south-central region of the state with operating dispensaries in Hanover, Mechanicsburg, and Annville. FLUENT FLUENT MECHANICSBURG Investor Presentation 10#11Texas#12Texas Summary We are one of only three vertical license holders in the second most populous state in the country. significant potential for 1st mover advantage Market dynamics are similar to Florida in 2016 - Medicinal uses for cannabis include epilepsy, terminal cancer, autism seizures and multiple sclerosis. Recent Texas legislation adds PTSD to the list of qualifying conditions, enables DPS to expand the medical cannabis program, and raises THC levels to 1% Existing cultivation facility in Schulenburg, TX with the right to expand up to 400,000 sq. ft. • 1,300 sq. ft. of cultivation space in climate and humidity-controlled C-containers Includes 1,920 sq. ft. of flowering canopy over 2 levels Recent Highlights: Recorded first B2B sale in TX in Q2 2023 Hired a President and dedicated team to run state operations Completed first sale of THC in April 2023 Implemented an advertising campaign to build awareness for new patients On track to open the Company's first delivery center in Houston, TX FLUENT Investor Presentation 12#13Investment Highlights OPERATIONAL IMPROVEMENTS HAVE TRANSLATED TO DRAMATICALLY IMPROVED FINANCIAL PERFORMANCE In million of dollars 2022 2023 YoY% Total Revenue $87.7 $97.3 11% Adjusted EBITDA (1) $25.1 $27.2 8% CANSORTIUM IS CAPITALIZING ON THIS SUCCESS AND PLAYING OFFENSE ■ Sixth largest dispensary/retail footprint in Florida, which has one of the country's largest state medical cannabis programs Investing to expand Florida's cultivation and dispensary network, and recently increased retail operations in Pennsylvania First-mover advantage in Texas provides high-value optionality Seeking strategic partnerships to accelerate near-term growth opportunities (1) Adjusted EBITDA is a non-IFRS financial measures that does not have any standardized meaning prescribed by IFRS and may not be comparable to similar measures presented by other companies. FLUENT Investor Presentation 13#14FLUENT CANNABIS CARE we speak cannabis [email protected]